Invivyd, Inc. Files 8-K on Delisting Concerns
Ticker: IVVD · Form: 8-K · Filed: Dec 27, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Dec 27, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Invivyd's in trouble, might get delisted.
AI Summary
Invivyd, Inc. filed an 8-K on December 27, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing indicates potential issues with Invivyd, Inc.'s continued listing on a stock exchange, which could impact its stock price and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock and operations.
Key Numbers
- 001-40703 — SEC File Number (Identifies the company's filing history with the SEC.)
- 85-1403134 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Adagio Therapeutics, Inc. (company) — Former Company Name
- December 27, 2024 (date) — Filing Date
- Waltham, MA (location) — Principal Executive Offices
FAQ
What specific listing rule or standard has Invivyd, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Invivyd, Inc. has failed to satisfy, only that a notice has been issued.
What is the expected timeline for Invivyd, Inc.'s potential delisting?
The filing does not provide a specific timeline for any potential delisting process.
Has Invivyd, Inc. taken any steps to address the listing deficiency?
The provided text of the 8-K does not detail any specific actions taken by Invivyd, Inc. to address the listing deficiency.
What is the significance of the former company name, Adagio Therapeutics, Inc.?
Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc., with a name change occurring on November 12, 2020.
Where are Invivyd, Inc.'s principal executive offices located?
Invivyd, Inc.'s principal executive offices are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
Filing Stats: 1,130 words · 5 min read · ~4 pages · Grade level 14.4 · Accepted 2024-12-27 16:13:10
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
- $1.00 — e "Common Stock"), had closed below the $1.00 per share minimum required for continue
Filing Documents
- ivvd-20241227.htm (8-K) — 50KB
- 0000950170-24-140800.txt ( ) — 173KB
- ivvd-20241227.xsd (EX-101.SCH) — 31KB
- ivvd-20241227_htm.xml (XML) — 5KB
01
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 27, 2024, Invivyd, Inc. (the "Company") received a deficiency letter (the " Letter") from the Nasdaq Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company's common stock, $0.0001 par value per share (the "Common Stock"), had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement"). The Letter has no immediate effect on the listing of the Common Stock, which continues to trade on The Nasdaq Global Market under the symbol "IVVD" at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of the Letter, or until June 25, 2025, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price for the Common Stock must be at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by June 25, 2025, the Company may be eligible for an additional 180 calendar day period to regain compliance. To qualify for this second compliance period , the Company would be required to transfer to The Nasdaq Capital Market (the "Capital Market") and meet the continued listing requirement for market value of publicly held shares on the Capital Market and all other applicable requirements for initial listing on the Capital Market, except for the Capital Market's bid price requirement . In addition, the Company would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period. As part of its review process to determine
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: December 27, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary